company background image
NATCOPHARM logo

NATCO Pharma NSEI:NATCOPHARM Stock Report

Last Price

₹1.17k

Market Cap

₹210.0b

7D

15.1%

1Y

88.5%

Updated

12 Jun, 2024

Data

Company Financials +

NATCO Pharma Limited

NSEI:NATCOPHARM Stock Report

Market Cap: ₹210.0b

NATCOPHARM Stock Overview

A pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs).

NATCOPHARM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance6/6
Financial Health6/6
Dividends4/6

NATCO Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NATCO Pharma
Historical stock prices
Current Share Price₹1,168.90
52 Week High₹1,189.00
52 Week Low₹618.65
Beta0.50
1 Month Change19.95%
3 Month Change19.59%
1 Year Change88.55%
3 Year Change3.37%
5 Year Change129.47%
Change since IPO6,393.89%

Recent News & Updates

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Recent updates

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

May 09
Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02
Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 22
NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Feb 16
Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Nov 30
Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 24
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Shareholder Returns

NATCOPHARMIN PharmaceuticalsIN Market
7D15.1%3.3%5.1%
1Y88.5%56.1%43.8%

Return vs Industry: NATCOPHARM exceeded the Indian Pharmaceuticals industry which returned 56.2% over the past year.

Return vs Market: NATCOPHARM exceeded the Indian Market which returned 43.4% over the past year.

Price Volatility

Is NATCOPHARM's price volatile compared to industry and market?
NATCOPHARM volatility
NATCOPHARM Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement6.7%
10% most volatile stocks in IN Market9.8%
10% least volatile stocks in IN Market4.5%

Stable Share Price: NATCOPHARM has not had significant price volatility in the past 3 months.

Volatility Over Time: NATCOPHARM's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19813,946Rajeev Nannapaneniwww.natcopharma.co.in

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.

NATCO Pharma Limited Fundamentals Summary

How do NATCO Pharma's earnings and revenue compare to its market cap?
NATCOPHARM fundamental statistics
Market cap₹209.98b
Earnings (TTM)₹13.88b
Revenue (TTM)₹41.27b

15.1x

P/E Ratio

5.1x

P/S Ratio

Is NATCOPHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NATCOPHARM income statement (TTM)
Revenue₹41.27b
Cost of Revenue₹7.17b
Gross Profit₹34.10b
Other Expenses₹20.22b
Earnings₹13.88b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)77.51
Gross Margin82.64%
Net Profit Margin33.64%
Debt/Equity Ratio6.2%

How did NATCOPHARM perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

12%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.